Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 31c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.99 -0.17%
Revenue Growth %: +17.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +17.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.03, $0.31 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $42.06 million versus the consensus estimate of $40.31 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
